ORI 9020

Drug Profile

ORI 9020

Alternative Names: ORI-9020

Latest Information Update: 25 Aug 2006

Price : $50

At a glance

  • Originator Utah State University
  • Class Antivirals; Oligonucleotides
  • Mechanism of Action DNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • No development reported Hepatitis B

Most Recent Events

  • 25 Aug 2006 No development reported - Preclinical for Hepatitis B treatment in USA (unspecified route)
  • 06 May 2003 Preclinical trials in Hepatitis B treatment in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top